ABL1 and leukemia: These results indicate that oral combination treatment with the more potent inhibitors SNG1153 and DA together is more effective than either agent alone, or a combination of SNG1153 with IM, in eliminating BCR-ABL+ blast cells able to generate aggressive leukemia in mice, with significantly enhanced survival of leukemic mice.